governanceshareholder meetingsanalyst coveragetransparency informationnewsroompress releaseseventsmedia kit company tigenix nv euronext brussels tig is an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platforms of allogeneic or donor derived expanded stem cells.two products from the adipose derived stem cell technology platform are currently in clinical development . cx601 is in phase iii for the treatment of complex perianal fistulas in crohn s disease patients . on july 4 2016 we entered into a licensing agreement with takeda a large pharmaceutical company active in gastroenterology under which takeda acquired the exclusive right to commercialize cx601 for complex perianal fistulas outside the united states . cx611 has completed a phase i sepsis challenge trial and a phase i ii trial in rheumatoid arthritis . effective july 31 2015 tigenix acquired coretherapix whose lead cellular product allocsc 01 is currently in a phase ii clinical trial in acute myocardial infarction ami . in addition the second product candidate from the cardiac stem cell based platform acquired from coretherapix allocsc 02 is being developed in a chronic indication.tigenix is based in leuven belgium and has operations in madrid spain . read more ... products read more ... latest news 22 september 2016 tigenix appoints dr. june almenoff to its board of directors en nl fr 20 september 2016 tigenix business and financial update for the first half 2016 en nl fr 2 august 2016 takeda and tigenix announce publication in the lancet of 24 week results of the phase 3 admire cd trial investigating cx601 in the treatment of complex perianal fistulas in patients with crohn s disease en nl fr 20 july 2016 cormorant asset management llc notifies 5.81 % shareholding in tigenix en nl 5 july 2016 takeda and tigenix enter into licensing agreement for ex u.s. rights to cx601 for the treatment of complex perianal fistulas in patients with crohn s disease en nl fr read more ... company slide deck2016 corporate presentation management presentationsfirst half 2016 business and financial update ecco plenary admire cd presentation tigenix ecco symposium presentations interview with de tijd 23 september 2015 mediafin investor night eng fr 23 september 2015 hy15 results webcast presentation 15 september 2015 1h 2015 results webcast recording september 2015 tigenix cx601 admire cd top line results webcast august 2015 tigenix at alliance for regenerative medicine conference march 2015 tigenix on kanaal z television november 2014 2016 tigenix legal privacy policy